^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | AVTX-006 (mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Excerpt:
The antitumor efficacy of OSI-027 was evaluated in PIK3CA mutant SKOV-3 ... human ovarian cancer xenograft models. In the SKOV-3 model, OSI-027 at 50 mg/kg once daily for 14 days resulted in significant TGI (100% median TGI) with 15% regression. In addition, twice daily dosing at 25 mg/kg twice daily corresponding to a total daily dose of 50 mg/kg resulted in comparable TGI (100% median TGI with 12% regression; Fig. 5A).
DOI:
10.1158/1535-7163.MCT-10-1099
